Marcelle Machluf
Gründer bei NanoGhost Ltd.
Profil
Marcelle Machluf is the founder of NanoGhost Ltd.
which was founded in 2019.
She is currently an Associate Professor at Technion-Israel Institute of Technology.
Dr. Machluf was an External Director at Erech Finance Cahalacha Ltd.
from 2010 to 2019.
Dr. Machluf has an undergraduate degree from The Hebrew University of Jerusalem and graduate and doctorate degrees from Ben-Gurion University of the Negev.
Aktive Positionen von Marcelle Machluf
| Unternehmen | Position | Beginn |
|---|---|---|
| Technion-Israel Institute of Technology | Corporate Officer/Principal | - |
NanoGhost Ltd.
 NanoGhost Ltd. Packaged SoftwareTechnology Services NanoGhost Ltd. is an Israeli biotech company that specializes in developing a drug delivery platform called Nano-Ghosts/NGs. The company is based in Netanya, Israel. The platform is highly selective and is derived from the cell membrane of mesenchymal stem cells (MSCs), which have a known affinity for cancer and sites of inflammation. The company was founded in 2019 by Marcelle Machluf. Yonatan Malca has been the CEO of the company since 2019. | Gründer | 14.08.2019 |
Ehemalige bekannte Positionen von Marcelle Machluf
| Unternehmen | Position | Ende |
|---|---|---|
| ERECH FINANCE CAHALACHA LTD | Direktor/Vorstandsmitglied | 27.10.2019 |
Ausbildung von Marcelle Machluf
| The Hebrew University of Jerusalem | Undergraduate Degree |
| Ben-Gurion University of the Negev | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| ERECH FINANCE CAHALACHA LTD | Health Technology |
| Private Unternehmen | 1 |
|---|---|
NanoGhost Ltd.
NanoGhost Ltd. Packaged SoftwareTechnology Services NanoGhost Ltd. is an Israeli biotech company that specializes in developing a drug delivery platform called Nano-Ghosts/NGs. The company is based in Netanya, Israel. The platform is highly selective and is derived from the cell membrane of mesenchymal stem cells (MSCs), which have a known affinity for cancer and sites of inflammation. The company was founded in 2019 by Marcelle Machluf. Yonatan Malca has been the CEO of the company since 2019. | Technology Services |
